Back to search
FDAFDA · Food and drugs·Recall number D-0327-2023

Abelcet (Amphotericin B Lipid Complex) Injection, 5 mg/mL, 100 mg vial, Rx only, Manufactured by Exelead, Inc., Indianapolis, IN 46268; Distributed by Leadiant Biosciences, Inc., Gaithersburg, MD 20878, NDC 57665-101-41

Published February 22, 2023 · Recall initiated: February 3, 2023

Summary

FDA records drug Class II recall D-0327-2023, published February 22, 2023 and initiated February 3, 2023. Recalling firm: Leadiant Biosciences, Inc.; Status: Terminated; Reported quantity: 31,879 vials; Lot: Lot#: 1203A, Exp. 5/11/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of assurance of sterility: Medial fill with presence of Cupriavidus pauculus.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Leadiant Biosciences, Inc.
Distributor
Nationwide USA
Lot
Lot#: 1203A, Exp. 5/11/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Abelcet (Amphotericin B Lipid Complex) Injection, 5 mg/mL, 100 mg vial, Rx only, Manufactured by Exelead, Inc., Indianapolis, IN 46268; Distributed by Leadiant Biosciences, Inc., Gaithersburg, MD 20878, NDC 57665-101-41 recalled?

Yes. FDA published recall D-0327-2023 on February 22, 2023. Reported hazard: Lack of assurance of sterility: Medial fill with presence of Cupriavidus pauculus.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail